- Home
- PDM vs KALV Comparison
PDM vs KALV Comparison
Compare PDM & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | KALV |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PDM | KALV |
|---|---|---|
| Price | $7.93 | $26.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $9.00 | ★ $32.60 |
| AVG Volume (30 Days) | 1.1M | ★ 5.0M |
| Earning Date | 04-30-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $564,994,000.00 | $50,000,000.00 |
| Revenue This Year | $4.21 | $185.42 |
| Revenue Next Year | $1.29 | $59.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $6.32 | $9.83 |
| 52 Week High | $9.19 | $26.85 |
Technical Indicators
Market Signals| Indicator | PDM | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 74.87 |
| Support Level | $7.55 | $14.45 |
| Resistance Level | $8.78 | N/A |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 18.04 | 54.55 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.